NCT01116622 - Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

Interventions

DRUG

Bexarotene (Targretin®)

Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2

DRUG

Erlotinib (Tarceva™)

Level -1 100mg Level I 100mg Level II 150mg Level III 150mg

Trial Locations (1)

Dartmouth-Hitchcock Medical Center, Lebanon